Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$33.94
▲ $1.31 (+4.0%)
Market data updated: 09/18 09:44 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/18/2026
Market Cap
$3.78B
Day Range
$32.95 - $34.31
52-Week Range
$10.83 - $41.14
Beta
—
Next Earnings
04.11.2026
AMLX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+165.8% (1Y)
Strengths: 12/25 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 65.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$33.32 vs. price $33.94 (-198.2%)
Fair Value
Signal tension
Growth scores strong (68/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
59
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
12d ago · $34.10
Evidence: Narrative Gap moved from 49 to 14 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
58
Value
38
Momentum
63
Risk
40
Sentiment
100
Fundamental
46
Institutional
33
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Amylyx Pharmaceuticals has centered on its strong performance and potential as a competitor in the GLP-1 drug market. Analysts highlight its promising drug candidate, which has shown encouraging results, drawing comparisons to industry leader Eli Lilly. Guggenheim raised its price target for Amylyx to $57, maintaining a "Buy" rating, while broader discussions emphasize its growth potential amid positive economic signals. The focus remains on its stock surge and investor interest.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Amylyx Pharmaceuticals, Inc.. News trend score: 100. Reason: 12 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
42
🎯 Conviction (vs. Emotion)
39
Psychology
82
Fundamentals
46
Technical
63
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+117%
Market Narrative
65
Fundamental Reality
39
Narrative Gap
+26
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
AMLX’s psychology is dominated by **Euphoria**, driven by extreme valuation (+89% above 200-day average) and perfect news sentiment (100/100), despite weak momentum (-11.7% ROC). The **narrative gap (+14)** and **herding behavior** (identical peer movement) suggest traders are prioritizing group momentum over fundamentals, while **confirmation bias** may blind them to revenue declines (-1.0%). The key tension lies between detached optimism (Euphoria) and latent volatility (1.15x ATR), raising the open question: *Will sentiment sustain despite deteriorating fundamentals?*
Updated: 09/08/2026, 08:59 PM
What could change this?
👥 What the crowd believes
"Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate."
"Amylyx Pharmaceuticals (AMLX) Blasted Nearly 79% Higher This Week"
"Guggenheim analyst raises Amylyx price target to $57"
"Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?"
🧠 Market Brain events driving this
📈 4D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Howard Marks — 18/100
🗣️ Why do they disagree?
The stark divide in verdicts for AMLX reflects deep methodological contrasts between risk-focused and growth-oriented investors. Walter Bagehot’s near-perfect score highlights the stock’s liquidity resilience, aligning with his credit-market pragmatism, while Peter Lynch’s mid-range score suggests the stock’s valuation already embeds its growth potential—something Lynch often warned against overpaying for. Meanwhile, defensive investors like Benjamin Graham and Howard Marks dismiss the stock outright, flagging valuation risks or late-cycle warning signs, whereas Fisher and Veblen’s mixed but higher scores hint at cautious optimism about its operational quality. The spectrum from Marks’ outright caution to Bagehot’s liquidity endorsement underscores how AMLX’s appeal hinges on whether one prioritizes stability (Graham, Marks) or adaptability (Lynch, Fisher) in uncertain conditions.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 66
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 58
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 56
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 56
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 32
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 31
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 30
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 18
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (6 bullish · 4 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-47.4%
ROA
-43.5%
ROIC
—
EPS
-$1.53
Cash
$226.65M
Total Debt
—
Current Ratio
14.27
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$33.94
Estimated Fair Value (DCF)
-$33.32
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-198.2%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-154.35M | $-141.61M |
| 2 | 19.4% | $-184.26M | $-155.09M |
| 3 | 13.8% | $-209.59M | $-161.84M |
| 4 | 8.1% | $-226.62M | $-160.54M |
| 5 | 2.5% | $-232.29M | $-150.97M |
Base FCF (last actual year)
$-123.48M
Terminal Value
$-3.66B
Present Value of Terminal Value
$-2.38B
Enterprise Value
$-3.15B
Net Debt
$0
Equity Value
$-3.15B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.23
Tangible Book Value per Share (Tangible NAV)
$3.23
Sentiment based on basic keywords (not AI) — 12 positive, 7 neutral, 1 negative out of the last 20 articles.
SeekingAlpha · 16.9.2026
SeekingAlpha · 10.9.2026
Yahoo · 9.9.2026
Business Wire · 9.9.2026
Business Wire · 8.9.2026
Yahoo · 8.9.2026
Yahoo · 1.9.2026
Motley Fool · 1.9.2026
Yahoo · 30.8.2026
Motley Fool · 30.8.2026
Yahoo · 27.8.2026
Simply Wall St. · 27.8.2026
Benzinga · 27.8.2026
Yahoo · 26.8.2026
Simply Wall St. · 26.8.2026
Benzinga · 22.8.2026
Motley Fool · 21.8.2026
Insider Monkey · 21.8.2026
Stocktwits · 21.8.2026
Business Wire · 20.8.2026
Amylyx Pharmaceuticals, Inc. (AMLX) currently has a StockIQ AI score of 59/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AMLX currently scores 59/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, AMLX's estimated fair value is -$33.32, which is 198.2% below the current price of $33.94. This is one valuation model among several signals in the fair-value category, not a price target.
AMLX's technical score is 63/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 65.5%; Free cash flow growth: 26.4%; Net income growth: 52.0%.
Based on the real signals StockIQ computed: Estimated fair value: -$33.32 vs. price $33.94 (-198.2%); ATR: 5.6% of price; Calmar: 0.24 (3y annualized return 22.0% / max drawdown 91.7%).
StockIQ has no recorded dividend payment history for AMLX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Firestone Karen | Exercise of Derivative Securities | 31.8.2026 | 25,000 | -25,000 | — |
| Firestone Karen | Exercise of Derivative Securities | 31.8.2026 | 25,000 | +25,000 | $5.05 |
| Firestone Karen | Exercise of Derivative Securities | 31.8.2026 | 25,000 | -25,000 | — |
| Firestone Karen | Exercise of Derivative Securities | 31.8.2026 | 25,000 | +25,000 | $1.76 |
| Mazzariello Gina | Grant/Award from Employer | 18.8.2026 | 21,284 | +21,284 | — |
| Bedrosian Camille L | Grant/Award from Employer | 18.8.2026 | 22,807 | +22,807 | — |
| Cohen Joshua B | Grant/Award from Employer | 18.8.2026 | 60,039 | +60,039 | — |
| Klee Justin B. | Grant/Award from Employer | 18.8.2026 | 60,039 | +60,039 | — |
| FRATES JAMES M | Grant/Award from Employer | 18.8.2026 | 22,807 | +22,807 | — |
| Mazzariello Gina | Open Market Sale | 10.7.2026 | 15,000 | -15,000 | $17.61 |
| Mazzariello Gina | Open Market Sale | 10.7.2026 | 179,090 | -15,000 | $17.61 |
| Mazzariello Gina | Open Market Sale | 9.7.2026 | 15,000 | -15,000 | $18.32 |
| Mazzariello Gina | Open Market Sale | 9.7.2026 | 194,090 | -15,000 | $18.32 |
| FONTEYNE PAUL R. | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| MILNE GEORGE M JR | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| Quimi Daphne | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| Firestone Karen | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| Zeiher Bernhardt G | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| MILNE GEORGE M JR | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| Quimi Daphne | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| FONTEYNE PAUL R. | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| Firestone Karen | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| Zeiher Bernhardt G | Grant/Award from Employer | 4.6.2026 | 24,372 | +24,372 | — |
| Firestone Karen | Open Market Purchase | 21.5.2026 | 3,800 | +3,800 | $13.51 |
| Firestone Karen | Open Market Purchase | 21.5.2026 | 66,900 | +3,800 | $13.51 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
12,737,201 shares short as of 2026-08-31 · vs. 13,401,722 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.8% of trading volume this week was short selling, vs. 61.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology